Slow-release ivermectin formulations for malaria vector control Current status and prospects Carlos Chaccour MD MSc.

Slides:

Advertisements

Similar presentations

NC STEP/Mission Hospitals School Cessation and Treatment Guide.

Advertisements

Syringe Driver Drugs.

Daniel Everitt, MD; Erica Egizi MPH Global Alliance for TB Drug Development, New York Helen Winter, PhD University of Otago, New Zealand 2012 International.

1 Rash and Low T2* MRI in a Paediatric Thalassaemia Patient.

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.

Kevin Kobylinski 1,2, Alongkot Ponlawat 2, Ratawan Ubalee 2, Brian Foy 3, Joel Tarning 4, Thanaporn Wattanakul 4, MAJ Wes McCardle 2, CDR Dan Szumlas 1,

Some remaining questions in particle therapy radiation biology Bleddyn Jones University of Oxford 1. Gray Institute for Radiation Oncology & Biology 2.

Planning for Success Biotechnology Product Development

Interchangeability and study design Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.

Routes of Drug Administration

Medicines and drugs Option D Part 1.

Concepts and Applications of Pharmacokinetics

Extended duration of injection interval. 2 Lucas et al. Efficacy of lanreotide Autogel ® administered every 4–8 weeks in patients with acromegaly previously.

Tutorial 1 January 18, 2013.

Nifedipine Overdose in a 2 year-old boy Dr. Jenny Lam AED PWH.

WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Artemisinin-based Products Dr. Henrike Potthast

1 Ensuring optimal breastfeeding and complementary feeding Dr Arun Gupta MD FIAP ICMR New Delhi 23 Feb 2011.

Pharmacology I BMS 242 Lecture I (Continued) Introduction; Scope of Pharmacology Routes of Drug Administration Dr. Aya M. Serry 2015/2016.

Principal Author, MD Second Author, MD PhD Third Author, MSc Institution, City, Country 23 January 2013.

Multiple dosing: intravenous bolus administration

WHO Prequalification Programme June 2007 Training Workshop on Dissolution, Pharmaceutical Product Interchangeability and Biopharmaceutical Classification.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.

1 Systemic Human Exposure of Pimecrolimus and Tacrolimus Following Topical Application Tapash K. Ghosh, Ph.D. Office of Clinical Pharmacology and Biopharmaceutics.

Locatelli F et al. Proc ASH 2013;Abstract 4378.

BIOPHARMACEUTICS.

Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology.

Pharmacodynamic Indices Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton.

Key data on young people’s mental health Ann Hagell Research Lead, Association for Young People’s Health.

Design of Sustained Release Dosage Forms

European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.

Interchangeability and study design Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.

415 PHT Plasma Level – Time Curve

Comparison of AzaSite® and Azithromycin 1% for Bacterial Conjunctivitis Christopher Crean 1, Jason L. Vittitow 1, Richard C. Zink 1, Lori Richards 1, Rozemarijn.

Routes of Drug Administration

Drug Response Relationships

1 Oliva EN et al Proc ASH 2015;Abstract 91.

Dissolution testing and in vitro in vivo correlation of conventional and SR preparations Formulation development and optimization is an ongoing process.

Introduction; Scope of Pharmacology Routes of Drug Administration

Addressing sleep problems- The role of long-acting opioids

Dunleavy K et al. Proc ASH 2015;Abstract 472.

Design and Analysis of Crossover Study Designs

containing the immobilized enzyme in a well-mixed state?

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo by Min.

A Six-hour Hemodialysis Without a Significant Increase in Dialysis Dose, as Judged by Kt/V, Can Reduce the Dosage of Erythropoietin Department of Kidney.

by Anita Hill, Peter Hillmen, Stephen J

Luke W. Hosack, MD, MS, Derek J. Overstreet, PhD, Evan S. Lederman, MD

Bioequivalence trials: design, evaluation, regulatory requirements

Impact of Tamsulosin OCAS on Energy of Patients with LUTS/BPH

Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer Jasmine.

Peak Plasma Concentrations After Oral Morphine

Hannah C. Slater, Lucy C. Okell, Azra C. Ghani Trends in Parasitology

Voriconazole tissue and fluid concentrations in humans as multiples of the maximal or simultaneously measured concentration in plasma (μg/ml) after systemic.

MIC distributions of selected β-lactam antimicrobial agents for H

Regulated P124SMEK1 expression cannot alter p-ERK levels or sensitivity to BRAF or MEK inhibition in V600EBRAF melanoma cell lines. Regulated P124SMEK1.

Figure Diagrammatic levodopa pharmacokinetics after single doses of immediate release (IR) carbidopa/levodopa (CD/LD) and 3 strengths of extended release.

Routes of Drug Administration

Nanoemulsions as Versatile Formulations for Paclitaxel Delivery: Peroral and Dermal Delivery Studies in Rats Sateesh Khandavilli, Ramesh Panchagnula

Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation Martin.

Development of stable STZ-induced diabetes requires coexisting diet-induced impaired glucose tolerance. Development of stable STZ-induced diabetes requires.

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

Drug levels during the course of a dosing interval.

Intrapatient variability in cyclosporine blood levels in renal transplant patients. Intrapatient variability in cyclosporine blood levels in renal transplant.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Effect of PDGF-BB on mesenchymal mesonephric cell migration.

The same daily dose of metformin administered as different dosage regimens has differing effects on the concentration–time profile in a patient with CKD.

Plasma concentration-time profile after oral administration of a single dose. Plasma concentration-time profile after oral administration of a single dose.

Fig. 1: Ampule of vitamin K

MET activation confers resistance to cetuximab (Cmab) or panitumumab (Pmab) in colon cancer cell lines in vitro and in vivo. MET activation confers resistance.

Presentation transcript:

Slow-release ivermectin formulations for malaria vector control Current status and prospects Carlos Chaccour MD MSc

Does IVM kill gambiae? Direct feedings 24 hours after 200mcg/kg JID 2010

How much IVM kills gambiae? The minimum insecticidal concentration 22.4 ng/ml (18-27 ng/ml) Kobylinski 2010 In vitro mixing + membrane 16 ng/ml (14-17 ng/ml) Kobylinski 2012 In vitro mixing + membrane 6 ng/ml (4-7 ng/ml) Bousema 2013 Volunteers + membrane

MIC + PK = The mosquitocidal window

22 ng/ml 18 hours

6 ng/ml 40 hours

Why is this important? A key factor for interrupting transmission would be the time IVM remains in blood above mosquito-killing levels (i.e the width of the window) (Slater et al 2014)

Widening the window Increase a single dose (mcg/kg) i.e. Higher Cmax Intermitent treatment i.e. Consecutive peaks Slow release ----> Alter the curve (!) Oral (bowel transit time) Parenteral

First attempt… Maeda 2003 Cunnigham 2006

3 formulations: F – M - X I – II – III per subject Cuantifications Weekly (12 weeks) Monthly (12-24 weeks) Extensive toxicology study

Stable concentrations can be safely achieved modifying the formulation Slow release technology available today The modelled impact on transmission is very promising

Prospects, gaps and message New slow release formulations Slow release pill Transdermal patches Pill + patch approach Pegilated subcutaneous Knowledge gaps Joint work on TPP

Juliane Chaccour. Ángel Irigoyen, Ana G. Gil, Felix Hammann, Jose L Del Pozo. The MISSION Team: Santi, Chema, Rocio, Isa, Alberto. Campaign supporters and donnors